Skip to main content
SpringerLink
Log in

Pharmacoeconomic Analysis Methods

  • Living reference work entry
  • First Online:
Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy

Abstract

In the last years, the growing interest of healthcare professionals, policy-makers, and other stakeholders in enlarging the role of economic evaluations was driven by several factors such as evidence-based healthcare culture, patient-centered actions, and quality-linked incentives, associated with an important increase of financial constraints and pressures on healthcare budgets. Pharmacoeconomics, as a branch of health economics, focuses on balancing the costs and benefits (i.e., consequences) of an intervention towards the use of limited resources, aiming at maximizing value to patients, healthcare payers, and society. These concepts are part of the Health Technology Assessment process that informs clinical and governmental players about medical, social, and economic implications of development, diffusion, and use of health technologies. This chapter aims to provide an overview of the important concepts in pharmacoeconomic analysis methods, including studies classification (e.g., budget-impact analysis, cost-minimization analysis, cost-effectiveness analysis, cost-utility analysis), types of costs and outcomes, modeling approaches (e.g., decision trees or state transition models), and new trending analysis (e.g., value of information and value-based healthcare analyses), and additionally discuss some recommendations for future studies towards evidence synthesis and practical application.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Ademi Z, Kim H, Zomer E, Reid CM, Hollingsworth B, Liew D. Overview of pharmacoeconomic modelling methods. Br J Clin Pharmacol. 2013;75(4):944–50.

    Article  PubMed  Google Scholar 

  • Allen N, Liberti L, Walker SR, Salek S. A comparison of reimbursement recommendations by European HTA agencies: is there opportunity for further alignment? Front Pharmacol. 2017;8:384.

    Article  PubMed  PubMed Central  Google Scholar 

  • Annemans L, Geneste B, Jolain B. Early modelling for assessing health and economic outcomes of drug therapy. Value Health. 2000;3(6):427–34.

    Article  CAS  PubMed  Google Scholar 

  • Basu A, Maciejewski ML. Choosing a time horizon in cost and cost-effectiveness analyses. JAMA. 2019;321(11):1096–7.

    Article  PubMed  Google Scholar 

  • Berger M. Willingness to pay versus willingness to buy: what defines value in healthcare? Value Health. 1998;1(4):201–3.

    Article  CAS  PubMed  Google Scholar 

  • Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925–30.

    Article  PubMed  PubMed Central  Google Scholar 

  • Boshuizen HC, van Baal PH. Probabilistic sensitivity analysis: be a Bayesian. Value Health. 2009;12(8):1210–4.

    Article  PubMed  Google Scholar 

  • Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-Severac H, Crawford B, et al. Identification, review, and use of health state Utilities in Cost-Effectiveness Models: an ISPOR good practices for outcomes research task force report. Value Health. 2019;22(3):267–75.

    Article  PubMed  Google Scholar 

  • Bridges JF. Future challenges for the economic evaluation of healthcare: patient preferences, risk attitudes and beyond. PharmacoEconomics. 2005;23(4):317–21.

    Article  PubMed  Google Scholar 

  • Briggs A, Clark T, Wolstenholme J, Clarke P, Missing... Presumed at random: cost-analysis of incomplete data. Health Econ. 2003;12(5):377–92.

    Article  PubMed  Google Scholar 

  • Chapko MK, Liu CF, Perkins M, Li YF, Fortney JC, Maciejewski ML. Equivalence of two healthcare costing methods: bottom-up and top-down. Health Econ. 2009;18(10):1188–201.

    Article  PubMed  Google Scholar 

  • Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13):1437–43.

    Article  CAS  PubMed  Google Scholar 

  • Damman OC, Jani A, de Jong BA, Becker A, Metz MJ, de Bruijne MC, et al. The use of PROMs and shared decision-making in medical encounters with patients: an opportunity to deliver value-based health care to patients. J Eval Clin Pract. 2020;26(2):524–40.

    Article  PubMed  Google Scholar 

  • Danzon PM, Drummond MF, Towse A, Pauly MV. Objectives, budgets, thresholds, and opportunity costs-a health economics approach: an ISPOR special task force report [4]. Value Health. 2018;21(2):140–5.

    Article  PubMed  Google Scholar 

  • Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.

    Google Scholar 

  • Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technol Assess. 2001;5(16):1–69.

    Article  CAS  PubMed  Google Scholar 

  • Elbasha EH, Chhatwal J. Myths and misconceptions of within-cycle correction: a guide for Modelers and decision makers. PharmacoEconomics. 2016;34(1):13–22.

    Article  PubMed  Google Scholar 

  • Epstein D, Sutton A. Modelling correlated clinical outcomes in health technology appraisal. Value Health. 2011;14(6):793–9.

    Article  PubMed  Google Scholar 

  • Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, et al. Value of information analysis for research decisions-an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23(2):139–50.

    Article  PubMed  Google Scholar 

  • Goodman C. HTA 101: introduction to health technology assessment. Bethesda: National Library of Medicine (US); 2014.

    Google Scholar 

  • Graves N, Walker D, Raine R, Hutchings A, Roberts JA. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Econ. 2002;11(8):735–9.

    Article  PubMed  Google Scholar 

  • Greenberg D, Mohamed Ibrahim MIB, Boncz I. What are the challenges in conducting cost-of-illness studies? Value Health Reg Issues. 2014;4:115–6.

    Article  PubMed  Google Scholar 

  • Hay JW. Economic modeling and sensitivity analysis. Value Health. 1998;1(3):187–93.

    Article  CAS  PubMed  Google Scholar 

  • Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–5.

    Article  PubMed  Google Scholar 

  • Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm. 1992;49(7):1741–7.

    CAS  PubMed  Google Scholar 

  • Kent S, Burn E, Dawoud D, Jonsson P, Ostby JT, Hughes N, et al. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics; 2020.

    Google Scholar 

  • Kim DD, Wilkinson CL, Pope EF, Chambers JD, Cohen JT, Neumann PJ. The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):615–23.

    Article  PubMed  Google Scholar 

  • McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D. The ISPOR good practices for quality improvement of cost-effectiveness research task force report. Value Health. 2009;12(8):1086–99.

    Article  PubMed  Google Scholar 

  • McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 1: introduction to the concepts of economic evaluation in health care. J Fam Plann Reprod Health Care. 2006;32(2):107–12.

    Article  PubMed  Google Scholar 

  • Murphy EM, Rodis JL, Mann HJ. Three ways to advocate for the economic value of the pharmacist in health care. J Am Pharm Assoc. 2003;60(6):e116–e24.

    Article  Google Scholar 

  • Nixon J, Stoykova B, Glanville J, Christie J, Drummond M, Kleijnen J. The U.K. NHS economic evaluation database. Economic issues in evaluations of health technology. Int J Technol Assess Health Care. 2000;16(3):731–42.

    Article  CAS  PubMed  Google Scholar 

  • Nuno-Solinis R. Advancing towards value-based integrated Care for Individuals and Populations. Int J Integr Care. 2019;19(4):8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Onukwugha E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-illness studies: an updated review of current methods. PharmacoEconomics. 2016;34(1):43–58.

    Article  PubMed  Google Scholar 

  • Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5. Value Health. 2012;15(6):828–34.

    Article  PubMed  PubMed Central  Google Scholar 

  • Rabarison KM, Bish CL, Massoudi MS, Giles WH. Economic evaluation enhances public health decision making. Front Public Health. 2015;3:164.

    Article  PubMed  PubMed Central  Google Scholar 

  • Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, et al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4(5):485–504.

    Article  PubMed  Google Scholar 

  • Sharma D, Aggarwal AK, Downey LE, Prinja S. National Healthcare Economic Evaluation Guidelines: a cross-country comparison. Pharmacoecon Open; 2021.

    Google Scholar 

  • Smith PC, Sagan A, Siciliani L, Panteli D, McKee M, Soucat A, et al. Building on value-based health care: towards a health system perspective. Copenhagen: European Observatory Policy Briefs; 2020.

    Google Scholar 

  • Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. PharmacoEconomics. 2008;26(2):131–48.

    Article  PubMed  Google Scholar 

  • Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14.

    Article  PubMed  Google Scholar 

  • Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):2302.

    Article  Google Scholar 

  • Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5(4):559–75.

    Article  CAS  PubMed  Google Scholar 

  • Tuffaha HW, Gordon LG, Scuffham PA. Value of information analysis in healthcare: a review of principles and applications. J Med Econ. 2014;17(6):377–83.

    Article  PubMed  Google Scholar 

  • Vreman RA, Geenen JW, Knies S, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG. The application and implications of novel deterministic sensitivity analysis methods. PharmacoEconomics. 2021;39(1):1–17.

    Article  PubMed  Google Scholar 

  • Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol. 1997;43(4):343–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Westra TA, Parouty MB, Wilschut JC, Boersma C, Postma MJ. Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis. Value Health. 2011;14(8):1173–4. author reply 4-5

    Article  PubMed  Google Scholar 

  • Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.

    Article  PubMed  Google Scholar 

  • Zhang X. Application of discrete event simulation in health care: a systematic review. BMC Health Serv Res. 2018;18(1):687.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Sciences Postgraduate Program, Federal University of Paraná, Curitiba, Brazil

    Fernanda S. Tonin & Leticia P. Leonart

  2. H&TRC – Health & Technology Research Center, ESTeSL – Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal

    Fernanda S. Tonin

  3. Business Administration and Management. Institute of Social and Political Sciences, University of Lisbon, Lisbon, Portugal

    Cesar Casas

Authors
  1. Fernanda S. Tonin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leticia P. Leonart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cesar Casas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernanda S. Tonin .

Section Editor information

  1. National Institute for Health and Care Excellence, London, United Kingdom

    Dalia Dawoud

  2. Department of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom

    Zaheer-Ud-Din Babar

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Tonin, F.S., Leonart, L.P., Casas, C. (2022). Pharmacoeconomic Analysis Methods. In: Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-50247-8_130-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-50247-8_130-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-50247-8

  • Online ISBN: 978-3-030-50247-8

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation